Chapter 3
Potential for Increased Investment Activity in 2025
U.S. Life Sciences Outlook 2025
2 Minute Read
2 Minute Read
Sales transactions of life sciences lab/R&D properties hit their lowest level in over a decade in 2024, largely due to high interest rates and weak supply-and-demand fundamentals.
CBRE Research projects marginally higher investment sales in 2025 for all commercial real estate sectors based on improved macroeconomic trends, lower interest rates and greater demand. Life sciences investment activity may see a slight uptick, although the sector’s surge in new supply in H1 2025 will be a headwind.
Figure 28: Annual Investment Volume of R&D Properties
While conventional office properties have seen cap rates jump to levels not seen in over a decade, cap rates for life sciences properties appeared to stabilize in 2024 and remained below levels a decade ago.
CBRE expects the 10-year Treasury yield to remain above 4% in 2025, suggesting that any potential decline in life sciences cap rates will be marginal.
Figure 29: Average Cap Rates for Office and R&D Properties
Related Insights
-
Press Release
Hotels confirm their resilience: over 90% of investors plan to maintain or increase capital allocations. Prague breaks into Europe's TOP 10 cities
22 October 2026
Europe's hotel sector is demonstrating exceptional resilience and consolidating its position among the key real estate asset classes. According to the latest survey by CBRE, the world's leading commercial real estate services firm, more than 90% of the investors surveyed plan to maintain or further increase the volume of capital directed into hotel properties this year. Appetite remains strong despite macroeconomic uncertainty and heightened geopolitical tension. Prague has also left a notable mark in the pan-European comparison, improving year on year to join the top ten most attractive investment destinations.